Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.
This finding has the potential to expand the current utility of the panel to identify an important subgroup of people who would benefit from less treatment, the firm said.
The UCSF Helen Diller Family Comprehensive Cancer Center has installed GenomOncology's GO Clinical Workbench to support the institution's UCSF500 NGS panel.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
